High disease activity at baseline does not prevent a remission in patients with systemic lupus erythematosus

Rheumatology

Volumn 38, Issue 8, 1999, Pages 724-727

  Formiga, F ^a   Moga, I ^a   Pac, M ^a   Mitjavila, F ^a   Rivera, A ^a   Pujol, R ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Flare; Remission; Systemic lupus erythematosus

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; CHLOROQUINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; PREDNISONE;

ADULT; ARTICLE; DISEASE ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REMISSION; SCORING SYSTEM; SYSTEMIC LUPUS ERYTHEMATOSUS; TIME;

ADULT; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PROGNOSIS; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX;

EID: 0032732329     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/38.8.724     Document Type: Article

References (22)

1. Krause G, Martin L, Fritzler M, Hart DA. Influence of Corynebacterium parvum-PER on disease progression in the NZB/W model of systemic lupus erythematosus. Int J Immunopharmacol 1992;14:35-41.
2. Hart DA, Garlepp M, Fritzler M. Plasma proteinase regulation during disease progression in murine models of SLE. J Clin Lab Immunol 1989;30:27-34.
3. Drenkard C, Villa AR, Garcia-Padilla A, Pérez-Vazquez ME, Alarcón-Segovia D. Remission of systemic lupus erythematosus. Medicine (Baltimore) 1996;75:88-99.
4. Dubois EL. Systemic lupus erythematosus: Recent advances in its diagnosis and treatment. Ann Intern Med 1956;45:163-84.
5. Ropes MW. Observation on the natural course of disseminated lupus erythematosus. Medicine (Baltimore) 1964;43:387-91.
6. Gladman DD, Urowitz MB, Keystone EC. Serologically active clinically quiescent systemic lupus erythematosus. A discordance between clinical and serologic features. Am J Med 1979;66:210-5.
7. Tozman EC, Urowitz MB, Gladman DD. Prolonged complete remission in previously severe SLE. Ann Rheum Dis 1982;41:39-40.
8. Bombardier C, Gladman DD, Urowitz MB, Karon D, Chang CH, Committee on Prognosis Studies in SLE. Derivation of SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40.
9. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
10. Fries JF, Holman HR. In: Systemic lupus erythematosus. A clinical analysis. Vol. VI. Philadelphia: WB Saunders, 1975:127-33.
11. Halberg P, Alsbjorn B, Trolle Balslov J, Gerstoft J, Lorenzen I, Ullman S et al. Systemic lupus erythematosus: Follow-up study of 148 patients I: Classification, clinical and laboratory finding, course and outcome. Clin Rheumatol 1987;6:13-21.
12. Meyer O, Molta C, Bourgeois P, Haim T, Kahn MF. Profil des anticorps antinucleaires dans 14 cas de lupus erythemateux systemiques eteints depuis plus de trois ans. Rev Rhum Mal Osteoartic 1990;57:599-603.
13. Heller CA, Schur PH. Serological and clinical remission in systemic lupus erythematosus. J Rheumatol 1985;12: 916-8.
14. Alvarado C, Alcocer-Varela J, Llorente L, Richaud-Patin I, Cerbon M, Alarcón-Segovia D. Effect of CD28 antibody on T cells from patients with systemic lupus erythematosus. J Autoimmun 1994;7:763-73.
15. López-Karpovich X, Cardiel M, Cárdenas R, Piedras J, Alarcón-Segovia D. Circulating-colony-forming units of granulocytes and monocytes/macrophages in systemic lupus erythematosus. Clin Exp Immunol 1989;77:43-6.
16. Markeljevic J, Batinic D, Uzarevic B, Bozikov J, Cikes N, Babic-Naglic D et al. Peripheral blood CD5+ B cell subset in the remission phase of systemic connective tissue diseases. J Rheumatol 1994;21:2225-30.
17. Koide J, Takano M, Takeuchi T, Hosono O, Amano K, Homma M et al. Direct demonstration of immunoregulatory T-cell defects in patients with systemic lupus erythematosus. Scand J Immunol 1986;23:449-59.
18. Alcocer-Valera J, Alarcón-Segovia D. Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus. J Clin Invest 1982;69:1388-92.
19. ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenber CGM. Predictive value of rises in anti-double stranded DNA antibody levels for disease exacerbation in systemic lupus erythematosus: a longterm prospective study. Arthritis Rheum 1990;33:634-43.
20. Swaak AJG, Groenwold J, Bronsveld W. Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus. Ann Rheum Dis 1986;45:359-66.
21. Esdaile JM, Joseph L, Abrahamowicz M, Li Y, Danoff D, Clarke AE. Routine immunologic test in systemic lupus erythematosus: is there a need for more studies? J Rheumatol 1996;23:1891-6.
22. Swaak AJG, Smeenk RJT. Following the disease course in systemic lupus erythematosus: are serologic variables of any use. J Rheumatol 1996;23:1842-4.